Violeta Jardin: Measuring Antifibrinolytic Effect to Improve Tranexamic Acid Safety
Violeta Jardin, General Manager at Haemoview Diagnostics, shared a post on LinkedIn about a recent article by Kaiki Oya et al, published in A and A Practice, adding:
“Tranexamic acid (TXA) is central to bleeding control in cardiac surgery, yet high cumulative dosing around cardiopulmonary bypass is linked to perioperative seizures and prolonged antifibrinolytic shutdown, particularly in patients with renal impairment.
This new case report of TXA-induced seizure immediately after CPB highlights the need for individualized TXA strategies and real-time assessment of its neuro- and haemostatic impact.
The ClotPro TPA-test offers the only viscoelastic quantification of TXA-induced inhibition of tPA-triggered fibrinolysis, allowing titration to effect rather than fixed dosing and supporting safer, lower-dose TXA regimens in high‑risk patients.
Yoshii et al. show that even a 1 g TXA bolus produces measurable, sustained antifibrinolytic activity, with TPA-test parameters closely tracking impaired eGFR—providing a practical tool to avoid TXA overdosing and balance bleeding, seizure, and thrombotic risk post‑cardiac surgery.”
Title: Tranexamic Acid-Induced Seizure After Cardiopulmonary Bypass: A Case Report
Authors: Kaiki Oya, Jun Maki, Midoriko Higashi

Read the Full Article on British Journal of Anaesthesia.
Title: Point-of-care testing for tranexamic acid efficacy: a proof-of-concept study in cardiac surgical patients
Authors: Ryogo Yoshii, Yuya Takahashi, Kenichi A. Tanaka, Hidetake Kawajiri, Teiji Sawa, Fumimasa Amaya, Satoru Ogawa

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 16:17Shailendra Singh: Bombay Hospital Jaipur Inaugurates New Facility with Voluntary Blood Donation Camp
-
Nov 13, 2026, 16:10Minka Zivkovic: UMC Utrecht Announces Research Analyst Vacancy in Thrombosis and Haemostasis
-
Nov 13, 2026, 16:02Rounak Dubey: Elsevier’s Upcoming Handbook Explores Digitalization in Transfusion Medicine
-
Nov 13, 2026, 15:50Maha Othman: CanVECTOR 2026 Highlights Research on Immunothrombosis and Cancer-Associated Thrombosis
-
Nov 13, 2026, 15:48Cedric Hermans: Advances in Gene Therapy for Haemophilia A
-
Nov 13, 2026, 15:45Strengthens Global Collaboration in Thrombosis and Hemostasis for 2027 – ISTH
-
Nov 13, 2026, 15:42David McIntosh: The Global Blood Shortage Crisis and the Urgent Need for National Action
-
Nov 13, 2026, 15:41JTH Highlights Future Directions in Thromboprophylaxis for Hospitalized Children
-
Nov 13, 2026, 15:21Wolfgang Miesbach։ Gene Therapy for Haemophilia B Is Cheaper Than Lifelong Factor IX Prophylaxis in Sweden